-
Why It’s Important to Advocate for our Disease
Like many of our readers at Pulmonary Fibrosis News, I hadn’t heard of this disease throughout the treatment of my symptoms and subsequent diagnosis. I did the “Google doctor search” and read many other reputable sites; such as research hospitals, The Pulmonary Fibrosis Foundation, and professional journals. What I found was not many people outside of the pulmonary fibrosis community were aware of the devastation this disease causes. When I mentioned this to my doctor he stated, “Pulmonary fibrosis is not a CHIC disease”. There is not a major backing to raise funds for those living with this disease.
It seems raising funds is left up to several pharmaceutical companies, The Pulmonary Fibrosis Foundation, National Institute of Health, and grass roots organizations to raise money at a local level. In recent news, The American Lung Association identifies pulmonary fibrosis as a condition they will provide monies for research. I find it amazing only within the past year this disease is being recognized by a national philanthropic organization whose main benefactors are lung patients. At least we are now recognized and somewhat supported in research by The American Lung Association.
After my diagnosis, I ordered the bracelets provided by the Pulmonary Fibrosis Foundation to pass out to my family and friends. Unbeknownst to me, a friend and co-worker ordered a bracelet for every staff member at my school to show a support of unity for me and my disease. It was surprising to say the least to see every member wearing the bracelets. I look at wearing the bracelet as a talking point for inquisitive people. If someone asks me what the bracelet signifies, they are going to hear a story. I have always felt this was my obligation to spread the word about pulmonary fibrosis and advocate for those who are unable to advocate for themselves.
After my transplant, I participated in several conferences with Genentech and Boehringer Ingelheim held at the Cleveland Clinic main campus. These companies have developed the only medicines (Esbriet and OFEV) on the market that may slow the progression of the disease. In addition, CHEST and The American Thoracic Society were partners in this conference. Myself and other patients shared our stories with the employees of the two pharmaceutical companies. By listening to our stories, the participants gained a significant grasp on what this disease is capable of doing.
I encourage everyone touched by this disease to advocate for more funds for research and care. Tell anyone who will listen your story. The disease is still an unknown to a majority of the population.
What can you or we do to advocate for pulmonary fibrosis?
Have you participated in any fundraising activities?
How can we get the word out about pulmonary fibrosis?
Log in to reply.